Clinical Trials
5 trialsNCT03122717 2026-04-29
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT03040973 2026-04-02
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Novartis
Phase 2 Active not recruiting
NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03944772 2025-01-30
ORCHARD
AstraZeneca
Phase 2 Active not recruiting
NCT04143607 2024-06-14
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting